Global Biopharma Company Signs Agreement to Use OmniComm Systems Tech Suite

Applied Clinical Trials

OmniComm Systems, Inc. continues to expand its role in the rare disease treatment area with a new agreement. An international biopharmaceutical company has signed a five-year contract to use OmniComm’s suite of eClinical solutions to build and manage global Phase III and Phase IV studies targeting rare pediatric diseases. 

For more information, click here.